P&G Stock Solid In Third Quarter As Prilosec OTC Off And Running
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble's ability to differentiate Prilosec OTC as a proton-pump inhibitor versus available H2 antagonist heartburn products could give the firm a competitive advantage in the category and garner positive Wall Street attention
You may also be interested in...
Comparative Advertising Heats Up As Heartburn OTCs Jockey For Position
The Rx-to-OTC switch of Procter & Gamble's Prilosec OTC proton pump inhibitor appears to have spawned a growing trend of comparative advertisements for OTC heartburn drugs
Comparative Advertising Heats Up As Heartburn OTCs Jockey For Position
The Rx-to-OTC switch of Procter & Gamble's Prilosec OTC proton pump inhibitor appears to have spawned a growing trend of comparative advertisements for OTC heartburn drugs
Comparative Advertising Heats Up As Heartburn OTCs Jockey For Position
The Rx-to-OTC switch of Procter & Gamble's Prilosec OTC proton pump inhibitor appears to have spawned a growing trend of comparative advertisements for OTC heartburn drugs